FDA — authorised 8 June 1984
- Application: NDA018760
- Marketing authorisation holder: TWI PHARMS
- Local brand name: TENORETIC 50
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 cardio selective betablocker in United States
FDA authorised cardio selective betablocker on 8 June 1984
Marketing authorisations
FDA — authorised 15 July 1988
- Application: ANDA072304
- Marketing authorisation holder: AIPING PHARM INC
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 31 May 1990
- Application: ANDA072302
- Marketing authorisation holder: AIPING PHARM INC
- Local brand name: ATENOLOL AND CHLORTHALIDONE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 17 September 1991
- Application: ANDA073026
- Marketing authorisation holder: PHARMOBEDIENT
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 19 December 1991
- Application: ANDA073543
- Marketing authorisation holder: NOVITIUM PHARMA
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 19 December 1991
- Application: ANDA073542
- Marketing authorisation holder: NOVITIUM PHARMA
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 27 December 1991
- Application: ANDA073352
- Marketing authorisation holder: WATSON LABS
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 27 December 1991
- Application: ANDA073353
- Marketing authorisation holder: WATSON LABS TEVA
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 24 January 1992
- Application: ANDA073457
- Marketing authorisation holder: MYLAN
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 28 April 1992
- Application: ANDA074099
- Marketing authorisation holder: NOVITIUM PHARMA
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 2 July 1992
- Application: ANDA073665
- Marketing authorisation holder: WATSON LABS
- Local brand name: ATENOLOL AND CHLORTHALIDONE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 30 October 1992
- Application: ANDA073676
- Marketing authorisation holder: SCS
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 30 March 1993
- Application: ANDA073476
- Marketing authorisation holder: SUN PHARM INDUSTRIES
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 30 March 1993
- Application: ANDA073475
- Marketing authorisation holder: SUN PHARM INDUSTRIES
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 29 April 1993
- Application: ANDA073582
- Marketing authorisation holder: SUN PHARM INDUSTRIES
- Local brand name: ATENOLOL AND CHLORTHALIDONE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 28 May 1993
- Application: ANDA073316
- Marketing authorisation holder: TEVA
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 28 May 1993
- Application: ANDA073315
- Marketing authorisation holder: TEVA
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 31 October 1993
- Application: ANDA074203
- Marketing authorisation holder: AUROBINDO PHARMA USA
- Local brand name: ATENOLOL AND CHLORTHALIDONE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 28 February 1994
- Application: ANDA074265
- Marketing authorisation holder: CHARTWELL RX
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 18 January 1995
- Application: ANDA074056
- Marketing authorisation holder: TEVA
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 17 July 1997
- Application: ANDA074101
- Marketing authorisation holder: PLIVA
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 30 July 1997
- Application: ANDA074499
- Marketing authorisation holder: SUN PHARM INDUSTRIES
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 24 September 1997
- Application: ANDA074107
- Marketing authorisation holder: PLIVA
- Local brand name: ATENOLOL AND CHLORTHALIDONE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 14 May 1998
- Application: ANDA074404
- Marketing authorisation holder: NOSTRUM LABS
- Local brand name: ATENOLOL AND CHLORTHALIDONE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 30 July 2004
- Application: ANDA076907
- Marketing authorisation holder: ABLE
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 28 January 2005
- Application: ANDA076900
- Marketing authorisation holder: ZYDUS PHARMS USA
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 31 July 2006
- Application: ANDA076969
- Marketing authorisation holder: SANDOZ
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 13 September 2006
- Application: ANDA077443
- Marketing authorisation holder: UNIQUE
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 18 May 2007
- Application: ANDA076640
- Marketing authorisation holder: NESHER PHARMS
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 31 October 2007
- Application: ANDA078512
- Marketing authorisation holder: AUROBINDO PHARMA
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 20 March 2008
- Application: ANDA077779
- Marketing authorisation holder: NESHER PHARMS
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 14 May 2008
- Application: ANDA077176
- Marketing authorisation holder: NESHER PHARMS
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 3 August 2009
- Application: ANDA076862
- Marketing authorisation holder: ACTAVIS LABS FL INC
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 25 September 2009
- Application: ANDA078254
- Marketing authorisation holder: NORTHSTAR HLTHCARE
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 22 July 2010
- Application: ANDA090615
- Marketing authorisation holder: WOCKHARDT BIO AG
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 15 December 2011
- Application: ANDA202033
- Marketing authorisation holder: MYLAN PHARMS INC
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 1 August 2012
- Application: ANDA090617
- Marketing authorisation holder: DR REDDYS LABS LTD
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 15 August 2012
- Application: ANDA078889
- Marketing authorisation holder: REDDYS
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 25 November 2016
- Application: ANDA204161
- Marketing authorisation holder: ACTAVIS ELIZABETH
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 26 January 2018
- Application: NDA210428
- Marketing authorisation holder: SPIL
- Local brand name: KAPSPARGO SPRINKLE
- Indication: CAPSULE, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 6 February 2018
- Application: ANDA204106
- Marketing authorisation holder: NOVAST LABS
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 26 October 2018
- Application: ANDA207465
- Marketing authorisation holder: CIPLA
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 19 December 2018
- Application: ANDA207206
- Marketing authorisation holder: VISUM PHARM
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 8 March 2019
- Application: ANDA210028
- Marketing authorisation holder: ZYDUS PHARMS
- Local brand name: ATENOLOL AND CHLORTHALIDONE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 21 November 2019
- Application: ANDA213136
- Marketing authorisation holder: UNICHEM
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 30 March 2020
- Application: ANDA203699
- Marketing authorisation holder: PHARMADAX
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 31 March 2020
- Application: ANDA203028
- Marketing authorisation holder: PHARMADAX
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 6 November 2020
- Application: ANDA205541
- Marketing authorisation holder: HETERO LABS LTD III
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 25 November 2020
- Application: ANDA213302
- Marketing authorisation holder: UNICHEM
- Local brand name: ATENOLOL AND CHLORTHALIDONE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 25 November 2020
- Application: ANDA211143
- Marketing authorisation holder: ALKEM LABS LTD
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 25 October 2021
- Application: ANDA215560
- Marketing authorisation holder: NOVITIUM PHARMA
- Local brand name: ATENOLOL AND CHLORTHALIDONE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 26 September 2022
- Application: ANDA214004
- Marketing authorisation holder: SUNSHINE
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 18 October 2022
- Application: ANDA215637
- Marketing authorisation holder: ACCORD HLTHCARE
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 12 June 2023
- Application: ANDA216916
- Marketing authorisation holder: GRANULES
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 7 August 2023
- Application: ANDA216509
- Marketing authorisation holder: GRANULES
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 15 August 2023
- Application: ANDA209272
- Marketing authorisation holder: LUPIN
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 26 July 2024
- Application: ANDA214110
- Marketing authorisation holder: ZHEJIANG JUTAI PHARM
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 25 June 2025
- Application: ANDA206980
- Marketing authorisation holder: IPCA LABS LTD
- Local brand name: METOPROLOL SUCCINATE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA
- Application: ANDA073317
- Marketing authorisation holder: APOTHECON
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA073318
- Marketing authorisation holder: APOTHECON
- Local brand name: ATENOLOL
- Indication: TABLET — ORAL
- Status: approved
Frequently asked questions
Is cardio selective betablocker approved in United States?
Yes. FDA authorised it on 8 June 1984; FDA authorised it on 15 July 1988; FDA authorised it on 31 May 1990.
Who is the marketing authorisation holder for cardio selective betablocker in United States?
TWI PHARMS holds the US marketing authorisation.